潼关黄金主要在中国从事黄金勘探、开采、加工、冶炼及销售业务。所得款项将用于收购从事矿山工程 及建设的目标公司，以提升黄金开采业务协同效应、提高运营效率及加强矿山安全生产控制。本次发行 根据股东大会授予的一般授权实施。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 来源：新浪港股-好仓工作室 2025年12月19日，潼关黄金（股份代号：00340）公告称，通过一般授权以"配售代价股份"方式融资， 其中配售代价股份发行110,000,000股（约1.1亿股），募集约2.9亿港元。 配售代价股份配售价2.60港元较前一交易日收市价2.75港元折让约5.5%，较前五个交易日平均收市价折 让约6.5%。配售股份占现有已发行股本约2. ...

Core Viewpoint - The company, 3SBio Inc., announced a financing plan through a general mandate by issuing new shares to Pfizer, raising approximately HKD 790 million, netting around HKD 790 million after expenses [1] Group 1: Financing Details - The company issued 31,142,500 shares (approximately 0.3 million shares) at a subscription price of HKD 25.21, representing a discount of about 17.1% compared to the previous trading day's closing price of HKD 30.40 [1] - The shares offered represent about 1.3% of the existing issued share capital and will also account for approximately 1.3% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 630 million of the raised funds will be allocated to enhance the global research and development pipeline for clinical and preclinical projects, as well as to improve production facilities [1] - About HKD 160 million will be used for other general corporate purposes [1] Group 3: Conditions for Completion - The completion of this issuance is subject to the fulfillment of conditions under the subscription agreement or any applicable waivers [1]